Dr. K. A. Kumar

Dr. K. A. "Ajay" Kumar obtained his Ph.D. in Organic/Medicinal Chemistry working in the area of Steroids, a phamaceutically important class of drugs.  Dr. Kumar also has a MBA in Finance from the globally recognised Rutgers Business School and was elected to the Beta Gamma Sigma Business Honor Society.

After completing his doctorate, Dr. Kumar completed a post-doctorate in strained molecules and high-energy molecules working mostly on projects for the Department of Energy. His work was internationally recognized with numerous publications in that area including some breakthrough work with difficult highly strained carbon skeletons.

In 1999, Dr. Kumar joined Fisher Scientific as Sr. Scientist and Process Development Manager and played a major part in integrating the IP from the Janssen Purchase of Kodak Chemicals and the eventual formation of the Acros divison of Fisher. He and his group were also very successful in the process development of various pharmaceutically important API and vitamins.

Dr. Kumar joined Taxolog in 2000 and directed the Drug Discovery and Drug Development groups including managing the preclinical and early clinical Drug Development Program in multi-therapeutic area. Some of the drugs that he and his group developed were licensed to  major pharmaceutical companies for oncology trials. He is an expert in evaluating drug candidates for their progression through the development chain.  He can evaluate the candidate molecules for in and out-licensing purposes taking into consideration the due scientific and financial complexities, and can also negotiate strategic alliances.  He also managed alliances with development partners during this period. Dr. Kumar has managed both preclinical and clinical CROs as well as the regulatory program needed for filing INDs, CTA/CTX and ANDAs.  He is also well versed in the application of financial and operational tools in business including design and implementing of strategy.  With his financial background he has invaluable experience in firm level valuations and can evaluate merger and acquistion scenarios, including valuations of difficult to evaluate young companies, IP rich companies and companies with negative growth and or hidden liabilities.He has over 36 patents and publications in prestigious peer reviewed journals.

Dr. Kumar is currently the Chief Scientific & Operations Officer and member of Symbiotic Research, LLC and has overall Senior General Management responsibility at the company.